SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?
Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.
How this was made
The 30-second read
Why it matters
The trial data represent a material clinical milestone that could accelerate FDA filing and drive near‑term stock momentum.
Market read
The breakthrough trial results are the primary catalyst for a 156% price jump, making the story highly relevant for traders.
What to watch
The $150 M share offering could dilute existing shareholders and temper upside if pricing is unfavorable.
Background
Sellas Life Sciences reported its Phase 3 Regal trial results, showing a median overall survival of 24 months versus 14.7 months for standard therapy.
Ticker impact
Phase 3 Regal trial showed a 9.3‑month overall survival benefit and 41% reduction in death risk, driving a 156% stock surge.
upward pressure as the market prices in the survival benefit and potential approval.
The data are statistically significant (hazard ratio 0.59, p‑value 0.035) and the stock already rallied sharply, indicating strong buyer interest.
Market effects
Biotech sector may see renewed interest in leukemia immunotherapies, lifting peers with similar pipelines.
U.S. biotech investors likely increase exposure; limited immediate effect on broader markets.
Positive data could attract international investors seeking high‑growth biotech exposure.
Counterpoint
If the FDA delays approval or requests additional data, the rally could reverse sharply.
Key entities
- companySellas Life Sciences
Biotech firm developing the GPS leukemia vaccine.
- analystMaxim Group
Raised price target to $40 on the trial results.

